These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
458 related articles for article (PubMed ID: 22516386)
21. Radiosensitivity enhancement by combined treatment of celecoxib and gefitinib on human lung cancer cells. Park JS; Jun HJ; Cho MJ; Cho KH; Lee JS; Zo JI; Pyo H Clin Cancer Res; 2006 Aug; 12(16):4989-99. PubMed ID: 16914589 [TBL] [Abstract][Full Text] [Related]
22. Molecular mechanisms underlying effects of epidermal growth factor receptor inhibition on invasion, proliferation, and angiogenesis in experimental glioma. Guillamo JS; de Boüard S; Valable S; Marteau L; Leuraud P; Marie Y; Poupon MF; Parienti JJ; Raymond E; Peschanski M Clin Cancer Res; 2009 Jun; 15(11):3697-704. PubMed ID: 19435839 [TBL] [Abstract][Full Text] [Related]
23. [Effect of gefitinib on radiosensitivity of gastric cancer cell lines]. Cao WG; Ma T; Li JF; Li H; Ji YB; Chen XH; Liu BY; Jin YN Ai Zheng; 2007 Dec; 26(12):1330-5. PubMed ID: 18076795 [TBL] [Abstract][Full Text] [Related]
25. Enhancement of glioblastoma radioresponse by a selective COX-2 inhibitor celecoxib: inhibition of tumor angiogenesis with extensive tumor necrosis. Kang KB; Wang TT; Woon CT; Cheah ES; Moore XL; Zhu C; Wong MC Int J Radiat Oncol Biol Phys; 2007 Mar; 67(3):888-96. PubMed ID: 17293239 [TBL] [Abstract][Full Text] [Related]
26. Targeting of AKT1 enhances radiation toxicity of human tumor cells by inhibiting DNA-PKcs-dependent DNA double-strand break repair. Toulany M; Kehlbach R; Florczak U; Sak A; Wang S; Chen J; Lobrich M; Rodemann HP Mol Cancer Ther; 2008 Jul; 7(7):1772-81. PubMed ID: 18644989 [TBL] [Abstract][Full Text] [Related]
27. The DNA-PK Inhibitor VX-984 Enhances the Radiosensitivity of Glioblastoma Cells Grown Timme CR; Rath BH; O'Neill JW; Camphausen K; Tofilon PJ Mol Cancer Ther; 2018 Jun; 17(6):1207-1216. PubMed ID: 29549168 [TBL] [Abstract][Full Text] [Related]
28. Interaction of ionizing radiation and ZRBA1, a mixed EGFR/DNA-targeting molecule. Heravi M; Rachid Z; Goudarzi A; Schlisser A; Jean-Claude BJ; Radzioch D; Muanza TM Anticancer Drugs; 2009 Sep; 20(8):659-67. PubMed ID: 19581798 [TBL] [Abstract][Full Text] [Related]
29. Blockage of epidermal growth factor receptor-phosphatidylinositol 3-kinase-AKT signaling increases radiosensitivity of K-RAS mutated human tumor cells in vitro by affecting DNA repair. Toulany M; Kasten-Pisula U; Brammer I; Wang S; Chen J; Dittmann K; Baumann M; Dikomey E; Rodemann HP Clin Cancer Res; 2006 Jul; 12(13):4119-26. PubMed ID: 16818713 [TBL] [Abstract][Full Text] [Related]
30. Inhibition of DNA-dependent protein kinase induces accelerated senescence in irradiated human cancer cells. Azad A; Jackson S; Cullinane C; Natoli A; Neilsen PM; Callen DF; Maira SM; Hackl W; McArthur GA; Solomon B Mol Cancer Res; 2011 Dec; 9(12):1696-707. PubMed ID: 22009179 [TBL] [Abstract][Full Text] [Related]
31. Suppression of DNA-dependent protein kinase sensitize cells to radiation without affecting DSB repair. Gustafsson AS; Abramenkovs A; Stenerlöw B Mutat Res; 2014 Nov; 769():1-10. PubMed ID: 25771720 [TBL] [Abstract][Full Text] [Related]
32. Blockade of TGF-β signaling by the TGFβR-I kinase inhibitor LY2109761 enhances radiation response and prolongs survival in glioblastoma. Zhang M; Kleber S; Röhrich M; Timke C; Han N; Tuettenberg J; Martin-Villalba A; Debus J; Peschke P; Wirkner U; Lahn M; Huber PE Cancer Res; 2011 Dec; 71(23):7155-67. PubMed ID: 22006998 [TBL] [Abstract][Full Text] [Related]
33. Combined inhibition of IGFR enhances the effects of gefitinib in H1650: a lung cancer cell line with EGFR mutation and primary resistance to EGFR-TK inhibitors. Choi YJ; Rho JK; Jeon BS; Choi SJ; Park SC; Lee SS; Kim HR; Kim CH; Lee JC Cancer Chemother Pharmacol; 2010 Jul; 66(2):381-8. PubMed ID: 19921194 [TBL] [Abstract][Full Text] [Related]
34. Antitumor activity of the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor gefitinib (ZD1839, Iressa) in non-small cell lung cancer cell lines correlates with gene copy number and EGFR mutations but not EGFR protein levels. Helfrich BA; Raben D; Varella-Garcia M; Gustafson D; Chan DC; Bemis L; Coldren C; Barón A; Zeng C; Franklin WA; Hirsch FR; Gazdar A; Minna J; Bunn PA Clin Cancer Res; 2006 Dec; 12(23):7117-25. PubMed ID: 17145836 [TBL] [Abstract][Full Text] [Related]
35. DNA-PKcs deficiency inhibits glioblastoma cell-derived angiogenesis after ionizing radiation. Liu Y; Zhang L; Liu Y; Sun C; Zhang H; Miao G; Di CX; Zhou X; Zhou R; Wang Z J Cell Physiol; 2015 May; 230(5):1094-103. PubMed ID: 25294801 [TBL] [Abstract][Full Text] [Related]
36. DNA-PKcs-dependent modulation of cellular radiosensitivity by a selective cyclooxygenase-2 inhibitor. Kodym E; Kodym R; Chen BP; Chen DJ; Morotomi-Yano K; Choy H; Saha D Int J Radiat Oncol Biol Phys; 2007 Sep; 69(1):187-93. PubMed ID: 17707272 [TBL] [Abstract][Full Text] [Related]
37. Enediyne lidamycin enhances the effect of epidermal growth factor receptor tyrosine kinase inhibitor, gefitinib, in epidermoid carcinoma A431 cells and lung carcinoma H460 cells. Liu H; Li L; Li XQ; Liu XJ; Zhen YS Anticancer Drugs; 2009 Jan; 20(1):41-9. PubMed ID: 19342999 [TBL] [Abstract][Full Text] [Related]
38. Met kinase inhibitor E7050 reverses three different mechanisms of hepatocyte growth factor-induced tyrosine kinase inhibitor resistance in EGFR mutant lung cancer. Wang W; Li Q; Takeuchi S; Yamada T; Koizumi H; Nakamura T; Matsumoto K; Mukaida N; Nishioka Y; Sone S; Nakagawa T; Uenaka T; Yano S Clin Cancer Res; 2012 Mar; 18(6):1663-71. PubMed ID: 22317763 [TBL] [Abstract][Full Text] [Related]
39. Insulin-like growth factor-1 receptor inhibition induces a resistance mechanism via the epidermal growth factor receptor/HER3/AKT signaling pathway: rational basis for cotargeting insulin-like growth factor-1 receptor and epidermal growth factor receptor in hepatocellular carcinoma. Desbois-Mouthon C; Baron A; Blivet-Van Eggelpoël MJ; Fartoux L; Venot C; Bladt F; Housset C; Rosmorduc O Clin Cancer Res; 2009 Sep; 15(17):5445-56. PubMed ID: 19706799 [TBL] [Abstract][Full Text] [Related]
40. EGFRvIII does not affect radiosensitivity with or without gefitinib treatment in glioblastoma cells. Struve N; Riedel M; Schulte A; Rieckmann T; Grob TJ; Gal A; Rothkamm K; Lamszus K; Petersen C; Dikomey E; Kriegs M Oncotarget; 2015 Oct; 6(32):33867-77. PubMed ID: 26418954 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]